Executive Team

About Us

Engineered BioPharmaceuticals is intently focused on lowering the cost of healthcare, both in the United States and throughout the World. The company believes one way to accomplish this is by making therapeutic drugs more accessible and user friendly – which will, in turn, increase patient adherence to prescribed medications and ensure diseases are slowed or prevented. When patients do not take their medicine and diseases are allowed to progress, the cost to patients, and society, is exponentially larger than the cost of the medicine itself.

Located in South Central Virginia, Engineered BioPharmaceuticals specializes in the development, formulation, and production of novel pharmaceutical delivery technologies. After fourteen plus years in this space, the company believes the clear winning delivery technology is the one that best fits into a patient’s normal lifestyle. To this end, the company is thrilled to announce its proprietary GelRx™ technology, specifically designed for the easy oral delivery of active pharmaceutical ingredients (APIs). Check back soon for more exciting news, including the company’s first prescription pharmaceutical and other pipeline products.

Executive Team

Carl R. Sahi
President and Co-founder

With 40 years of experience in early stage corporate and new business development, Carl has facilitated the development of innovative technologies yielding sustainable products in the fields of biotechnology, medical devices and pharmaceuticals. Carl has been the co-founder and President of four previous companies, including the publicly traded Bio-Plexus, Inc. Carl graduated from the University of Connecticut with a Bachelor of Science degree in Pathobiology and a Masters of Science degree in Pharmacology and Toxicology from Michigan State University.

Jack M. Polidoro
Vice President, R&D and Co-founder

Jack received a Master of Science degree in Biomedical Engineering from Yale University and Bachelor of Science degrees in Mechanical Engineering and Material Science from the University of Connecticut. Jack has been in the business of developing and designing medical devices for more than twenty five years. In 1992 he began his career as a product engineer at Bio-Plexus, a start-up safety needle company, eventually becoming the Director of Technology and New Business Development. After leaving Bio-Plexus, Jack co-founded a boutique engineering consulting firm, a Visionary Company where he has developed numerous medical devices for medical device and pharmaceutical clients, including several advanced drug delivery products. Jack is a named inventor on seventeen patents and has numerous patents in pending. In September 2009, Jack was a contributing author on “Inspiratory Efforts Achieved in Use of the Technosphere Insulin Inhalation System”, an article published in the Journal of Diabetes Science and Technology.

Mark E. Ketner
Senior Engineer and Principal Investigator

Mark holds a Ph.D. in Biomedical Engineering from the University of North Carolina at Chapel Hill and a Bachelor of Science in Chemical Engineering from North Carolina State University. With 15 years of experience in the processing of pharmaceuticals, Mark has extensive knowledge and experience with the production of pharmaceutical powders using spray drying and lyophilization techniques as well as knowledge in analytic and physical testing of pharmaceutical powders. Mark most recently worked with Becton Dickenson (BD) developing the atmospheric spray-freeze-drying (ASFD) process. His work at BD, funded by the United States Army Medical Research Institute for Infectious Disease, resulted in stable, aerodynamically light dry powders suitable for bio-defense vaccines for counterterrorism measures. Before working with BD, Mark worked for Oriel Therapeutics, Inc. as a Design Engineer. At Oriel Therapeutics, Inc., he contributed to the development of multi-dose dry powder inhalers and was a contributor on several patents. Before working at BD, Mark worked as an Engineer for Experimental Cardiology Group where he was responsible for the acquisition, monitoring and feedback control of cardiac electrolytes.

© 2011 - 2024 / Engineered BioPharmaceuticals, All Rights Reserved